OREGON CLINICAL & TRANSLATIONAL RESEARCH INSTITUTE

Biomedical Innovation Program (BIP) Drug Discovery

REQUEST FOR APPLICATIONS

The Oregon Clinical & Translational Research Institute (OCTRI) in partnership with OHSU Innovates, is accepting applications for the Biomedical Innovation Program (BIP) Drug Discovery track

PROGRAM OVERVIEW

BIP Drug Discovery supports and accelerates creative, interdisciplinary drug discovery and therapeutic development research at OHSU. Examples of responsive application topics include but are not limited to development and validation of drug targets, screening platforms, small molecules, antibodies, vaccines, biologics, and novel methodologies that improve the efficiency of drug discovery.

Grants will be awarded on a competitive basis, with budgets not to exceed $60,000. Additionally, each awardee will be assigned a project manager and a mentor to advise and help accelerate their project towards commercialization. Projects will typically be supported for a 12-month period; predetermined milestones and quantitative metrics of success will be evaluated on a regular basis.

APPLICATION PROCESS OVERVIEW

1. Complete a **Technology Disclosure Form** and submit to OHSU Technology Transfer (if not previously submitted).
2. Submit via REDCap here:
    a. Research plan no more than **5 pages** long. Please use the **template** provided on page 3. References do not count toward page total.
    b. NIH 398 budget & budget justification
    c. NIH biosketches for PI and key personnel
    d. *Optional* Letters of support (up to 3)
3. Projects selected to advance will be invited to participate in a Q&A with review committee members
4. Finalists will be invited to present to the review committee, after which, final funding decisions will be made.

KEY DATES

Application deadline: **5/07/25**
Q&A with reviewers: **6/04/25**
Final presentation: **6/25/25**

NEED ASSISTANCE WITH YOUR APPLICATION?

To learn more about the BIP or to schedule a consult, please contact:

Jonathan Jubera, M.B.A.
OCTRI Senior Project Manager
jubera@ohsu.edu

APPLICATION RESOURCES ARE AVAILABLE AT:

www.ohsu.edu/octri-bip

All application materials are treated as confidential documents. Confidentiality agreements are in place with all members of the review committee

REVIEW CRITERIA

- **Leverage Pilot Funding:** How will this funding move the technology to the next phase of development?
- **Impact to Human Health:** Does the proposed work aim to solve an important problem or remove a critical barrier to progress in the field? How will the project move the technology closer to benefiting human health?
- **Market Need Addressed:** What is the market need (number of patients likely affected, expected savings in health care/societal expenditures, etc.)? How many potential applications or products could come from the proposed technology?
- **Project Design and Feasibility:** Is the proposed work feasible? What types of expertise will be leveraged to move the technology forward? What are the potential barriers, and what is the plan to overcome them?
- **Innovation and Novelty:** Is the technology novel, useful, non-obvious, and enabled?
- **Commercialization Potential:** What is the commercialization strategy and path(s) to secure additional funding? Are there target entities identified as potential partners or licensees? Is there interest and potential for creating a start-up?
- **Strength of Team:** The investigators must have the requisite skills and experience to carry out the project successfully.

CONTRIBUTION TO TRANSLATIONAL SCIENCE (OPTIONAL, FOR OCTRI TRACKING & REPORTING)

The goal of translational science is to identify and remove barriers, roadblocks, or bottlenecks in the translational research process. This approach **solves problems that will benefit research across a range of diseases and conditions and accelerate health solutions to people**. **If applicable**, applicants are encouraged to describe how their proposed project or technology could contribute to translational science.

How to think about translational science for your proposed pilot project:

- What is the translational roadblock, barrier, or unmet need being addressed?
- What is the project that you propose to lessen or remove the roadblock?
- How will these findings increase translational efficiency and produce generalizable knowledge across therapeutic areas, contexts, etc.?

Providing this information is not part of the project selection rubric and does not count toward the 5-page limit. There will be a field to provide this information on the REDCap submission form.

ELIGIBILITY

BIP Drug Discovery is open to all employees and students of OHSU, with these important caveats:

- If either human subjects or animals are included in the project scope of work, the applicant MUST meet OHSU Principal Investigator requirements.
- Non-faculty applicants must submit written approval from their supervisor or department head authorizing "effort" on the grant – including the specific amount.

PROJECTS INVOLVING HUMAN SUBJECTS RESEARCH AND/OR LIVE VERTEBRATE ANIMAL STUDIES

In addition to IRB/IACUC approval, the National Center for Advancing Translational Science (NCATS) must approve human subjects research and/or live vertebrate animal projects before any funding can be released. Applicants are strongly urged to complete the required components of the NCATS submission(s) during the application phase to reduce the time to funding. Please contact Bridget Adams, OCTRI Regulatory Knowledge and Support Manager, for a list of the required elements and assistance: adamsb@ohsu.edu; 503-494-5077.

POST -AWARD PROCESSES

All award recipients will be required to submit progress reports using guidelines that will be provided at a later date.

BIOMEDICAL INNOVATION PROGRAM (BIP) DRUG DISCOVERY – APPLICATION TEMPLATE

Please use this template and the headings below but delete all italicized instructions before uploading via REDCap. ***Application should not exceed 5 pages – excluding references.***

PRINCIPAL INVESTIGATOR (NAME AND TITLE):

PROJECT TITLE:

BACKGROUND/UNMET NEED: *The unmet or poorly met clinical need or disease, including the current approaches for assessment or treatment of your chosen clinical problem and the known shortcomings of those approaches.*

PROPOSED TECHNOLOGY AND SOLUTION *A description of the proposed solution and the advantages it would have compared to current approaches. Include preliminary data.)*

MARK ET OPPORTUNIT Y: *What is clinically significant about your proposed drug or therapeutic? Please outline the market need for drug or therapeutic, including metrics such as the number of patients likely affected, expected savings in health care/societal expenditures, etc.*

COMPETITION: *Identify competing solutions clinicians currently use for this problem. How is your technology different and/or superior?*

TARGET PRODUCT PROFILE. *Please address the elements of the target product profile to the extent possible. Include some quantitative measures such as minimum potency in vitro and/or in vivo, and minimum ADME/toxicology parameters.*

INTELLECTUAL PROPERTY: *Intellectual property status, strategy, and future plan. Include invention disclosures, filed patent applications, IP ownership shared with others, patents awarded and/or technologies licensed, and third- party existing IP related to your proposed drug or therapeutic.*

R& D TIMELINE AND BUDGET: *Outline 12-month project timeline and milestones. Estimate total R&D and/or development timeline (i.e., "bench to bedside" time). Include a gross estimate of the direct R&D costs for study personnel, minor equipment, and supplies (do not add in the university overhead) for the award period.* ***Please include commercial planning activities in this section.***

COMMERCIALIZATION POTENTIA L: *Describe a strategy for pursuing additional funding (e.g., sponsored research agreements, industry partners, or additional grants to further commercial development after BIP funding ends). What is the planned or desired commercialization path: licensing the technology to an existing company or forming a startup company?*

T EA M MEMBERS: *List team members, their expertise, and project role.*

This funding mechanism is supported by the National Center for Advancing Translational Science (UL1TR002369) and the OHSU Foundation/University Venture Development Fund (UVDF). It is open to all OHSU faculty and qualified employees who meet eligibility requirements.